Literature DB >> 18406574

Osteopontin promoter polymorphism is associated with increased carotid intima-media thickness.

Lisa de las Fuentes1, C Charles Gu, Santhosh J Mathews, Joann L Reagan, Nicholas P Ruthmann, Alan D Waggoner, Chung-Fang Lai, Dwight A Towler, Víctor G Dávila-Román.   

Abstract

BACKGROUND: Osteopontin (OPN)-transgenic mice exhibit increased carotid artery intima-media thickness (CIMT), smooth muscle cell proliferation, and atheroma formation.
METHODS: An association of the human T-66G promoter variant with CIMT was examined in Caucasian adults grouped according to metabolic syndrome criteria: present (+MetS; n = 70) or absent (-MetS; n = 70).
RESULTS: The G-allele frequency was 22%. For the entire cohort, the G group (TG and GG) was associated with significantly lower age-adjusted and gender-adjusted CIMT compared with the TT group (P = .008); similar analysis by metabolic syndrome group found a significant difference only in the -MetS group (P = .018). Stepwise multivariate regression showed that after age and waist circumference, the T-66G variant was the next most predictive of CIMT (P = .007). These data suggest that in a normoglycemic environment, human vascular OPN gene expression contributes to arterial structure, an effect diminished in dysmetabolic states.
CONCLUSION: Humans with the OPN -66 TT genotype, particularly those without metabolic syndrome, exhibit thicker CIMT.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18406574      PMCID: PMC2536614          DOI: 10.1016/j.echo.2008.02.005

Source DB:  PubMed          Journal:  J Am Soc Echocardiogr        ISSN: 0894-7317            Impact factor:   5.251


  53 in total

Review 1.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.

Authors:  D T Denhardt; M Noda; A W O'Regan; D Pavlin; J S Berman
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

2.  Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study.

Authors:  Anthony J G Hanley; Ken Williams; Michael P Stern; Steven M Haffner
Journal:  Diabetes Care       Date:  2002-07       Impact factor: 19.112

3.  Pure atmospheric pressure promotes an expression of osteopontin in human aortic smooth muscle cells.

Authors:  K Iizuka; T Murakami; H Kawaguchi
Journal:  Biochem Biophys Res Commun       Date:  2001-05-04       Impact factor: 3.575

Review 4.  Osteopontin: a versatile regulator of inflammation and biomineralization.

Authors:  C M Giachelli; S Steitz
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

Review 5.  Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly.

Authors:  Zorina S Galis; Jaikirshan J Khatri
Journal:  Circ Res       Date:  2002-02-22       Impact factor: 17.367

6.  Atorvastatin inhibits hypercholesterolemia-induced cellular proliferation and bone matrix production in the rabbit aortic valve.

Authors:  Nalini M Rajamannan; Malayannan Subramaniam; Margaret Springett; Thomas C Sebo; Marek Niekrasz; Joseph P McConnell; Ravinder J Singh; Neil J Stone; Robert O Bonow; Thomas C Spelsberg
Journal:  Circulation       Date:  2002-06-04       Impact factor: 29.690

7.  Enhanced expression of osteopontin in human diabetic artery and analysis of its functional role in accelerated atherogenesis.

Authors:  M Takemoto; K Yokote; M Nishimura; T Shigematsu; T Hasegawa; S Kon; T Uede; T Matsumoto; Y Saito; S Mori
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-03       Impact factor: 8.311

8.  Osteopontin plays an important role in the development of medial thickening and neointimal formation.

Authors:  Kikuo Isoda; Kenichirou Nishikawa; Yashuhiro Kamezawa; Mikoto Yoshida; Masatoshi Kusuhara; Masao Moroi; Norihiro Tada; Fumitaka Ohsuzu
Journal:  Circ Res       Date:  2002-07-12       Impact factor: 17.367

9.  Concerted regulation of inorganic pyrophosphate and osteopontin by akp2, enpp1, and ank: an integrated model of the pathogenesis of mineralization disorders.

Authors:  Dympna Harmey; Lovisa Hessle; Sonoko Narisawa; Kristen A Johnson; Robert Terkeltaub; José Luis Millán
Journal:  Am J Pathol       Date:  2004-04       Impact factor: 4.307

10.  Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo.

Authors:  Mei Y Speer; Marc D McKee; Robert E Guldberg; Lucy Liaw; Hsueh-Ying Yang; Elyse Tung; Gerard Karsenty; Cecilia M Giachelli
Journal:  J Exp Med       Date:  2002-10-21       Impact factor: 14.307

View more
  12 in total

Review 1.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

Review 2.  Molecular determinants of the cardiometabolic phenotype.

Authors:  Lisa de las Fuentes; Giovanni de Simone; Donna K Arnett; Víctor G Dávila-Román
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2010-06       Impact factor: 2.895

3.  SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy.

Authors:  E Pegoraro; E P Hoffman; L Piva; B F Gavassini; S Cagnin; M Ermani; L Bello; G Soraru; B Pacchioni; M D Bonifati; G Lanfranchi; C Angelini; A Kesari; I Lee; H Gordish-Dressman; J M Devaney; C M McDonald
Journal:  Neurology       Date:  2010-12-22       Impact factor: 9.910

4.  Quantitative genetic study of the circulating osteopontin in community-selected families.

Authors:  S Ermakov; A Leonov; S Trofimov; I Malkin; G Livshits
Journal:  Osteoporos Int       Date:  2010-10-22       Impact factor: 4.507

5.  Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy.

Authors:  Santhosh Jay Mathews; Lisa de Las Fuentes; Prashanth Podaralla; Anton Cabellon; Sijie Zheng; Andrew Bierhals; Karen Spence; Eduardo Slatopolsky; Victor G Davila-Roman; James A Delmez
Journal:  Am J Nephrol       Date:  2011-01-17       Impact factor: 3.754

6.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

7.  Serum osteopontin, but not OPN gene polymorphism, is associated with LVH in essential hypertensive patients.

Authors:  Xuwei Hou; Zhaohui Hu; Xiaohua Huang; Yan Chen; Xiuying He; Haiying Xu; Ningfu Wang
Journal:  J Mol Med (Berl)       Date:  2013-12-27       Impact factor: 4.599

8.  The St. Louis African American health-heart study: methodology for the study of cardiovascular disease and depression in young-old African Americans.

Authors:  Robin R Bruchas; Lisa de Las Fuentes; Robert M Carney; Joann L Reagan; Carlos Bernal-Mizrachi; Amy E Riek; Chi Charles Gu; Andrew Bierhals; Mario Schootman; Theodore K Malmstrom; Thomas E Burroughs; Phyllis K Stein; Douglas K Miller; Victor G Dávila-Román
Journal:  BMC Cardiovasc Disord       Date:  2013-09-08       Impact factor: 2.298

9.  Thicker Carotid Intima Media Thickness in Children with Monocyte Chemoattractant Protein-1: A-2138T and A-2464G Mutation.

Authors:  Yuyun Yueniwati; Valentina Yurina; Mohammad Rasjad Indra
Journal:  Neurol Res Int       Date:  2014-04-22

10.  Genetic variations in the osteopontin promoters T-443C and G-156GG increase carotid intima-media thickness.

Authors:  Yuyun Yueniwati; Valentina Yurina; Nurus Sobah; Endang Rahayu
Journal:  Int J Gen Med       Date:  2016-05-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.